Advances in Antipsychotics

Antipsychotics are a class of psychiatric medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally for schizophrenia and bipolar disorder, and are increasingly being used in the management of non-psychotic disorders (ATC code N05A). First-generation antipsychotics, known as typical antipsychotics, neuroleptics or major tranquilizers, were discovered in the 1950s. Most second-generation drugs, known as atypical antipsychotics, have been developed more recently. Both generations of medication tend to block receptors in the brain’s dopamine pathways, but atypicals tend to act on serotonin receptors as well.


In the present book, ten typical literatures about antipsychotics published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on medical science, neurology, psychology, ect. We hope this book can demonstrate advances in antipsychotics as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    Adjusting for Geographic Variation in Observational Comparative Effectiveness Studies: A Case Study of Antipsychotics Using State Medicaid Data
  • Chapter 2
    Antipsychotic Patterns of Use in Patients with Schizophrenia: Polypharmacy versus Monotherapy
  • Chapter 3
    Asymmetric Dimethylarginine in Somatically Healthy Schizophrenia Patients Treated with Atypical Antipsychotics: A Case–Control Study
  • Chapter 4
    Attitudes towards the Administration of Longacting Antipsychotics: A Survey of Physicians and Nurses
  • Chapter 5
    Health Care Resource Utilization and Direct Medical Costs for Patients with Schizophrenia Initiating Treatment with Atypical Versus Typical Antipsychotics in Tianjin, China
  • Chapter 6
    Interaction between COMT rs5993883 and Second Generation Antipsychotics Is Linked to Decreases in Verbal Cognition and Cognitive Control in Bipolar Disorder
  • Chapter 7
    Canadian Clinical Practice Guidelines for the Management of Anxiety, Posttraumatic Stress and Obsessive-Compulsive Disorders
  • Chapter 8
    Patterns of Initiation of Second Generation Antipsychotics for Bipolar Disorder: A Month-by-Month Analysis of Provider Behavior
  • Chapter 9
    Study Protocol: Safety Correction of High Dose Antipsychotic Polypharmacy in Japan
  • Chapter 10
    The Efficacy and Safety of Once-Daily Quetiapine Extended Release in Patients with Schizophrenia Switched srom Other Antipsychotics: An Open-Label Study in Chinese Population
Readership: Students, academics, teachers and other people attending or interested in Advances in Antipsychotics
Elisabeth Dowling Root
Department of Geography and Institute for Behavioral Science, University of Colorado, Boulder, USA

Xiaoning He
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China

Stephanie A. Flowers
PhD, Clinical Pharmacy Department, College of Pharmacy, University of Michigan, Michigan, USA

Martin A. Katzman
Department of Psychiatry, University of Toronto, Toronto, Canada

Tsuruhei Sukegawa
National Hospital Organization, Tottori Medical Center, Tottori, Japan

Pei-Yin Pan
Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan

and more...
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.